Patients matching the codes for acute lymphoblastic leukemia (ALL, C91.0), acute myeloid leukemia (AML, C92.0), immunodeficiency (D84.9), myelodysplastic syndrome (MDS, D46), severe aplastic anemia (SAA, D61.9), HSCT (Z94.84) and prophylactic antifungal use (Z29.9).
Conditions
Interventions
Group 1: Eligible patients from the Department of Pediatric Hematology and Oncology will be identified using the department’s ICD-10 diagnosis registry and the department’s ICD-10 based database of pr
Sponsors
Universitätsklinikum Freiburg, Kinder- und Jugendklinik
Eligibility
Sex/Gender
All
Age
No minimum to 18 Years
Inclusion criteria
Inclusion criteria: • Presence of (= 1) high-risk criteria for IFD according to ECIL-8 recommendations (Groll, Pana et al. 2021): ? AML and relapsed / refractory AML ? high-risk ALL and relapsed / refractory ALL ? chronic granulomatous disease and other immunodeficiencies requiring HSCT ? myelodysplastic syndrome requiring HSCT ? refractory cytopenia of childhood (RCC) requiring immunosuppressive therapy or HSCT ? SAA requiring immunosuppressive therapy or HSCT ? any other disease requiring an allogenic HSCT ? persistent severe neutropenia (absolute neutrophile count (ANC) 10 days) • HSCT performed and / or intensive chemotherapy started between 01 January 2016 and 30 August 2020, and between 01 October 2024 and 30 September 2025. • Informed consent to Hilda Biobank
Exclusion criteria
Exclusion criteria: • Absence of high-risk criteria for IFD • Patients not treated within the above-mentioned time period • Absence of informed consent to Hilda Biobank
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Incidence of IFD according to EORTC/MSG criteria in the two cohorts | — |
Secondary
| Measure | Time frame |
|---|---|
| Use of prophylactic systemic antifungal agents, the management of proven, probable, and possible IFD, and patient’s outcome. | — |
Countries
Germany
Contacts
Public ContactAlexander Puzik
Universitätsklinikum Freiburg
Outcome results
None listed